Trial Profile
Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Head and neck cancer; Malignant thymoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.